Literature DB >> 7726537

Inhibitory action of lansoprazole and its analogs against Helicobacter pylori: inhibition of growth is not related to inhibition of urease.

K Nagata1, E Takagi, M Tsuda, T Nakazawa, H Satoh, M Nakao, H Okamura, T Tamura.   

Abstract

The proton pump inhibitors omeprazole and lansoprazole and its acid-activated derivative AG-2000, which are potent and specific inhibitors of urease of Helicobacter pylori (K. Nagata, H. Satoh, T. Iwahi, T. Shimoyama, and T. Tamura, Antimicrob. Agents Chemother. 37:769-774, 1993), inhibited the growth of H. pylori. The growth was inhibited not only in urease-positive clinical isolates but also in their urease-negative derivatives which had no urease polypeptides. AG-1789, a derivative of lansoprazole with no inhibitory activity against H. pylori urease, also inhibited the growth of both strains even more strongly than the urease inhibitors lansoprazole and AG-2000. Furthermore, the antibacterial activity of omeprazole and lansoprazole was not affected by glutathione or dithiothreitol, which completely abolished the inhibitory activity of lansoprazole against H. pylori urease. These results indicated that the inhibitory action of these compounds against the growth of H. pylori was independent from the inhibitory action against urease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7726537      PMCID: PMC162584          DOI: 10.1128/AAC.39.2.567

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.

Authors:  T Iwahi; H Satoh; M Nakao; T Iwasaki; T Yamazaki; K Kubo; T Tamura; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Omeprazole, Helicobacter pylori, gastritis, and duodenal ulcer.

Authors:  G Biasco; M Miglioli; L Barbara; R Corinaldesi; G di Febo
Journal:  Lancet       Date:  1989-12-09       Impact factor: 79.321

3.  Purification and N-terminal analysis of urease from Helicobacter pylori.

Authors:  L T Hu; H L Mobley
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

4.  Ultrastructural localisation of urease in outer membrane and periplasm of Campylobacter pylori.

Authors:  G Bode; P Malfertheiner; M Nilius; G Lehnhardt; H Ditschuneit
Journal:  J Clin Pathol       Date:  1989-07       Impact factor: 3.411

5.  Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.

Authors:  B J Marshall; J R Warren
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

Review 6.  Campylobacter pylori and gastroduodenal disease.

Authors:  G E Buck
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

7.  Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.

Authors:  H Nagaya; H Satoh; K Kubo; Y Maki
Journal:  J Pharmacol Exp Ther       Date:  1989-02       Impact factor: 4.030

8.  A urease-negative mutant of Helicobacter pylori constructed by allelic exchange mutagenesis lacks the ability to colonize the nude mouse stomach.

Authors:  M Tsuda; M Karita; M G Morshed; K Okita; T Nakazawa
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

9.  Two-dimensional gel electrophoresis and immunoblotting of Campylobacter pylori proteins.

Authors:  B E Dunn; G I Perez-Perez; M J Blaser
Journal:  Infect Immun       Date:  1989-06       Impact factor: 3.441

10.  Topographic association between active gastritis and Campylobacter pylori colonisation.

Authors:  E Bayerdörffer; H Oertel; N Lehn; G Kasper; G A Mannes; T Sauerbruch; M Stolte
Journal:  J Clin Pathol       Date:  1989-08       Impact factor: 3.411

View more
  11 in total

1.  Ulcerative typhlocolitis associated with Helicobacter mastomyrinus in telomerase-deficient mice.

Authors:  K A Eaton; J S Opp; B M Gray; I L Bergin; V B Young
Journal:  Vet Pathol       Date:  2010-10-06       Impact factor: 2.221

2.  Basis for the selective antibacterial activity in vitro of proton pump inhibitors against Helicobacter spp.

Authors:  J E Sjøstrøm; T Kühler; H Larsson
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Real-world Helicobacter pylori diagnosis in patients referred for esophagoduodenoscopy: The gap between guidelines and clinical practice.

Authors:  Dor Shirin; Shay Matalon; Benjamin Avidan; Efrat Broide; Haim Shirin
Journal:  United European Gastroenterol J       Date:  2016-01-08       Impact factor: 4.623

4.  Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro.

Authors:  P D Midolo; J D Turnidge; J R Lambert; J M Bell
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  Inhibitory activities of lansoprazole against respiration in Helicobacter pylori.

Authors:  K Nagata; N Sone; T Tamura
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

6.  Antimicrobial activity of novel furanonaphthoquinone analogs.

Authors:  K Nagata; K I Hirai; J Koyama; Y Wada; T Tamura
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

7.  Urease-independent chemotactic responses of Helicobacter pylori to urea, urease inhibitors, and sodium bicarbonate.

Authors:  T Mizote; H Yoshiyama; T Nakazawa
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

Review 8.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

9.  Lansoprazole Novel Effector Sites Revealed by Autoradiography: Relation to Helicobacter pylori, Colon, Esophagus and Others.

Authors:  Masahiko Nakamura; Hidenori Matsui; Hiroshi Serizawa; Kanji Tsuchimoto
Journal:  J Clin Biochem Nutr       Date:  2007-11       Impact factor: 3.114

10.  A cell-based high-throughput screen identifies drugs that cause bleeding disorders by off-targeting the vitamin K cycle.

Authors:  Xuejie Chen; Caihong Li; Da-Yun Jin; Brian Ingram; Zhenyu Hao; Xue Bai; Darrel W Stafford; Keping Hu; Jian-Ke Tie
Journal:  Blood       Date:  2020-08-13       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.